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Conversion from Recombinant Human Erythropoietin
to Once Every 4 Weeks Darbepoetin Alfa for Treatment
of Renal Anemia in CAPD Patients
Hon-Lok Tang, Ka-Shun Fung, Kwok-Hong Chu, William Lee, Au Cheuk, Ka-Fai Yim,
Hilda Wai-Han Chan, Kwok-Lung Tong
Background: Darbepoetin alfa is a new erythropoietic protein with a three-fold longer half-life than recombinant
human erythropoietin (rHuEPO), allowing for an extended dosing interval of once every 2 weeks in patients
with chronic renal failure. The objective of this study was to investigate the possibility of further extending the
dose interval of this erythropoietic agent to once every 4 weeks in the treatment of renal anemia in dialysis
patients.
Methods: A prospective study was carried out in 14 continuous ambulatory peritoneal dialysis (CAPD) patients
stably maintained on subcutaneous rHuEPO with hemoglobin level of 10–13 g/dL. They were switched to
subcutaneous darbepoetin alfa administered once every 4 weeks for a period of 24 weeks. The starting dose
was 40 µg. The dose of darbepoetin alfa was then adjusted to maintain a target hemoglobin level between 10
and 13 g/dL. When darbepoetin alfa was increased by 100%, the dosing interval was shortened to maintain the
target hemoglobin. Evaluation was done during the last 4 weeks.
Results: Of the 14 patients recruited, 11 patients completed the study. Of these 11 patients, 9 (82%) successfully
maintained the target hemoglobin with once every 4 weeks darbepoetin alfa. For those successful patients, the
mean hemoglobin level during the evaluation period was 11.13 ± 2.04 g/dL (mean ± standard deviation), and
the mean change in hemoglobin level from baseline was –1.03 g/dL (95% CI: –2.34, 0.27). The mean weekly
darbepoetin alfa dose requirement during the evaluation period was 12.33 ± 4.80 µg/week, and the mean
change in weekly dose from baseline was +2.33 µg/week (95% CI: –1.35, 6.02). No serious adverse event
related to darbepoetin alfa occurred during the study.
Conclusion: Darbepoetin alfa administered once every 4 weeks effectively maintained hemoglobin level in
most CAPD patients after conversion from previously stabilized rHuEPO treatment. Darbepoetin alfa is safe
and well tolerated, allowing for less frequent dosing. [Hong Kong J Nephrol 2007;9(2):77–81]
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INTRODUCTION
Anemia secondary to chronic renal failure has been
associated with cardiovascular complications including
left ventricular hypertrophy [1] and congestive heart
failure [2], reduced cognitive function [3], decreased
quality of life [3,4] and, more importantly, mortality
[5]. Recombinant human erythropoietin (rHuEPO) has
been the mainstay therapy of renal anemia since its
introduction over two decades ago [6,7]. However,
rHuEPO needs to be administered frequently up to three
times a week to be effective.
Darbepoetin alfa is a new erythropoietic protein
which stimulates erythropoiesis by the same mechanism
as endogenous erythropoietin and rHuEPO. Research
has indicated that sialic acid-containing carbohydrate
of erythropoietin determines its serum half-life [8].
Recombinant HuEPO has three N-linked carbohydrate
side chains, while darbepoetin alfa has five. The
increased carbohydrate content of darbepoetin alfa
results in a longer terminal half-life when compared
with rHuEPO. In dialysis patients, darbepoetin alfa has
been shown to have a serum half-life three times longer
than that of rHuEPO, accommodating extended dosing
intervals [9].
The efficacy and safety of administering darbepoetin
alfa once weekly or once every 2 weeks has been
demonstrated in patient with end-stage renal failure
[10]. The objective of this study was to investigate the
possibility of further extending the dose interval of
darbepoetin alfa to once every 4 weeks in the treatment
of renal anemia in dialysis patients.
PATIENTS AND METHODS
A prospective open-label study was carried out in 14
end-stage renal failure patients receiving continuous
ambulatory peritoneal dialysis (CAPD). The study was
approved by the research ethics committee of Princess
Margaret Hospital, Hong Kong. All patients gave
written informed consent before recruitment into the
study. Patients eligible for recruitment were those on
CAPD, and receiving subcutaneous rHuEPO with
hemoglobin level stably maintained between 10 and
13 g/dL for the past 3 months. Patients with
uncontrolled hypertension (defined as diastolic blood
pressure * 110 mmHg), New York Heart Association
Class III or IV congestive heart failure, grand mal
epilepsy, any kind of blood loss causing iron depletion,
vitamin B12 or folate deficiency, aluminium toxicity
and severe hyperparathyroidism (defined as parathyroid
hormone level > 20 times normal) were excluded from
the study. The presence of infection within the past 3
months, inflammatory conditions, malignancies, any
type of thalassemia and hematologic diseases that might
interfere with the erythropoietic response, were also
exclusion criteria. Those who had received blood trans-
fusion within 3 months before the screening period,
and pregnant and lactating females were also excluded.
Darbepoetin alfa was supplied by the hospital
pharmacy as a sterile protein solution in pre-filled
syringes containing 20 µg and 40 µg of the drug. The
14 enrolled patients were switched from subcutaneous
rHuEPO to subcutaneous darbepoetin alfa which was
administered once every 4 weeks. The starting dose was
40 µg, which was equivalent to an average weekly dose
of 10 µg. The dose of darbepoetin alfa was adjusted to
maintain a target hemoglobin level between 10 and 13
g/dL. Dose adjustments were made by 20 µg increments
or decrements when the hemoglobin levels were outside
the target range. If the hemoglobin level was still below
the target range after the darbepoetin alfa dose had been
increased by 100%, the dose interval was reduced by 1
week. Subjects were followed-up for a period of 24
weeks. Evaluation was done during the last 4 weeks of
the study. Complete blood count, transferrin saturation,
serum ferritin, albumin, urea and creatinine levels were
monitored every 4 weeks. Any requirement for blood
transfusion was recorded. Blood pressure and adverse
events were closely monitored.
The primary end point of the study was the
percentage of patients who were able to maintain the
target hemoglobin level of 10–13 g/dL with once every
4 weeks dosing during the evaluation period. The
secondary end points were the mean changes in
hemoglobin level and weekly dose of darbepoetin alfa
from baseline to evaluation period in those patients who
successfully maintained the target hemoglobin.
Statistical analysis
The number and percentage of patients who completed
the study and successfully maintained hemoglobin
above the target level (hemoglobin level * 10 g/dL)
during the evaluation period are presented. The mean
changes in hemoglobin level and weekly darbepoetin
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alfa dose from baseline to evaluation period for those
successful patients are presented, with two-sided 95%
confidence intervals (CIs). The non-parametric
Wilcoxon signed rank test was used to compare the
means of transferrin saturation and serum ferritin level
at baseline and evaluation period. A p value < 0.05 was
regarded as statistically significant.
RESULTS
Fourteen patients were enrolled in the study. Eleven of
the 14 patients completed the study. Of the three
patients who withdrew from the study prior to
completion, one died of infection, one inadvertently
injected conventional rHuEPO and one chose to
discontinue before completion of the study because of
mild elevation of blood pressure after receiving the
drug. For the 11 patients who completed the study, the
mean dose requirement of rHuEPO before entering the
study was 55.42 ± 21.01 U/kg/week (range, 27.78 ±
91.91 U/kg/week). Their primary renal pathologies
included unknown pathology (6 patients), diabetic
nephropathy (3 patients), polycystic kidney disease (1
patient) and IgA nephropathy (1 patient). The
demographic data and baseline characteristics of the
patients are shown in Table 1.
During the evaluation period, nine of the 11 patients
(82%) successfully maintained the target hemoglobin
level with once every 4 weeks darbepoetin alfa. The
two unsuccessful patients required an increase in the
frequency of darbepoetin alfa to once every 3 weeks to
maintain the target hemoglobin level. For the nine
successful patients, the mean hemoglobin level during
the evaluation period was 11.13 ± 2.04 g/dL, and the
mean change in hemoglobin level from baseline was
–1.03 g/dL (95% CI: –2.34, 0.27) (Table 2, Figure 1).
The mean weekly darbepoetin alfa dose requirement
during the evaluation period was 12.33 ± 4.80 µg/week,
and the mean change in weekly dose from baseline was
+2.33 µg/week (95% CI: –1.35, 6.02) (Table 3, Figure
2). From Table 1, six of the 11 studied patients were
receiving rHuEPO less frequently than once weekly
before entering the study. One of these six patients
belonged to the unsuccessful group. In the successful
group, four patients were receiving rHuEPO with
frequency not less than once weekly.
No significant changes in transferrin saturation and
serum ferritin level were observed during the evaluation
period (Table 3). No intravenous iron was required
during the study period. None of the patients had blood
transfusion given during the study. No serious adverse
events occurred during the study period. One death
occurred during the study due to infection which was
not considered to be related to darbepoetin alfa. No
clinically significant changes in other laboratory values
were observed. None of the patients had any change in
the peritoneal dialysis dose during the study period.
DISCUSSION
Recombinant HuEPO has been the mainstay therapy
in the treatment of renal anemia. However, due to its
relatively short half-life, rHuEPO needs to be
administered frequently up to three times a week.
Darbepoetin alfa has a three-fold longer half-life than
rHuEPO. This unique characteristic allows it to be
administered in an extended dose interval that is more
convenient for patients. Previous studies have
demonstrated the efficacy of darbepoetin alfa when
given once weekly [10–15] or once every 2 weeks [10,
14–17] to both dialysis and pre-dialysis chronic renal
failure patients with renal anemia. These studies also
found that, in contrast to rHuEPO, there was no
difference in intravenous and subcutaneous dose
requirements for darbepoetin alfa [10,14].
The present study aimed to evaluate the efficacy of
subcutaneous darbepoetin alfa in CAPD patients when
further extending the dose interval to once every 4
weeks. The majority (82%) of our patients successfully
maintained the target hemoglobin level after conversion
from rHuEPO to darbepoetin alfa. There was only
Table 1. Demographic and baseline characteristics of patients
(n = 11)*
Sex
Male 9 (82)
Female 2 (18)
Race
Chinese 11 (100)
Age (yr) 60.0 ± 12.9
Dialysis modality
Peritoneal dialysis 11 (100)
Baseline rHuEPO dose (U/kg/wk) 55.42 ± 21.01
Frequency of rHuEPO
Once per wk 5 (45)
Once every 10 d 4 (36)
Once every 2 wk 2 (18)
Baseline hemoglobin level (g/dL) 12.20 ± 1.43
Transferrin saturation (%) 44.45 ± 11.95
Ferritin (ng/mL) 785 ± 672
*Data are presented as n (%) or mean ± standard deviation. rHuEPO
= recombinant human erythropoietin.
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minimal increase in darbepoetin alfa dose requirement
towards the end of the study. Since 50% of the
unsuccessful patients were receiving rHuEPO less
frequently than once weekly and 44% of the successful
patients were receiving rHuEPO with frequency not less
than once weekly before recruitment, it is unlikely that
the less frequent rHuEPO dosing in some of our pa-
tients could account for the successful switching to
darbepoetin alfa once every 4 weeks. The mean base-
line rHuEPO dose requirement (55.42 U/kg/week) was
low in our patients. This is speculated to be due to
race effects, since Chinese patients may have a lower
erythropoietin requirement.
Recently, two studies have demonstrated that a
monthly dosing interval of darbepoetin alfa effectively
maintained hemoglobin level in dialysis patients [18,
19]. In one of the studies by the Darbepoetin Alfa
20000144 Study Group, the median weekly dose of
darbepoetin alfa required at the end of the study was
22 µg/week [18]. In the other study by Theodoridis et
al [19], a 200 IU rHuEPO to 1 µg darbepoetin alfa ratio
was used to calculate the weekly starting dose, in
accordance with the novel erythropoiesis-stimulating
protein (NESP) usage guidelines group [20]. In the
current study, the starting dose (average weekly dose)
of darbepoetin alfa was 10 µg/week, which was lower
than that used in the above two studies. The weekly
dose conversion ratio was approximately 275 IU
rHuEPO to 1 µg darbepoetin alfa. The same starting
dose was used in all patients. The dose requirement
was then adjusted to maintain the target hemoglobin
level, and the final mean weekly darbepoetin alfa dose
at the evaluation period was 12 µg/week, which was
still below the doses used in the above two studies.
Table 2. Changes in hemoglobin level and weekly darbepoetin alfa dose from baseline to evaluation period in successful patients (n = 9)
Baseline Evaluation period Mean change
(mean ± SD) (mean ± SD) (95% CI)
Hemoglobin (g/dL) 12.17 ± 1.47 11.13 ± 2.04 –1.03 (–2.34, 0.27)
Weekly darbepoetin alfa dose (µg/wk) 10.00 ± 0.00 12.33 ± 4.80 +2.33 (–1.35, 6.02)
SD = standard deviation; CI = confidence interval.
Table 3. Serum transferrin saturation and ferritin levels at baseline and the evaluation period in successful patients (n = 9)*
Baseline Evaluation period p
Transferrin saturation (%) 45.2 ± 13.1 51.4 ± 12.3 0.207
Ferritin (ng/mL) 701 ± 702 854 ± 470 0.214
*Data are presented as mean ± standard deviation.
Figure 1. Mean hemoglobin level in successful patients. The bars
represent 95% confidence intervals.
Figure 2. Mean weekly darbepoetin dose in successful patients.
The bars represent 95% confidence intervals.
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The iron status in our patients was not affected by
conversion to darbepoetin alfa. Both the transferrin
saturation and serum ferritin level remained unchanged
and no intravenous iron therapy was required by the
patients. No serious adverse events related to
darbepoetin alfa had occurred.
This prospective study demonstrated that
darbepoetin alfa administered once every 4 weeks
effectively maintained hemoglobin in most CAPD
patients after conversion from previously stabilized
rHuEPO treatment. Darbepoetin alfa is safe and well
tolerated, allowing for less frequent dosing, which may
confer significant advantages to patients by decreasing
the number of injections required. Nevertheless, the
present study, although prospective, was not a
randomized, controlled and large-scale study, and the
follow-up period did not exceed 6 months. Therefore,
a long-term, large-scale, randomized study is warranted
to confirm the results.
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